# | Date | Analyst Firm | Upside/Downside | Price Target Change | Rating Change | Current Rating |
---|
Barclays analyst Matt Miksic maintains Abbott Laboratories (NYSE:ABT) with a Overweight and raises the price target from $15...
Abbott eyes 10% EPS growth in 2026 with CGM momentum, new nutrition contracts, and medical device launches driving global expan...
Raymond James analyst Jayson Bedford maintains Abbott Laboratories (NYSE:ABT) with a Outperform and raises the price target ...
Evercore ISI Group analyst Vijay Kumar maintains Abbott Laboratories (NYSE:ABT) with a Outperform and lowers the price targe...
RBC Capital analyst Shagun Singh reiterates Abbott Laboratories (NYSE:ABT) with a Outperform and maintains $147 price target.
Wells Fargo analyst Lawrence Biegelsen maintains Abbott Laboratories (NYSE:ABT) with a Overweight and raises the price targe...
Wall Street rose on Wednesday, with investor optimism lifted by strong bank and corporate earnings alongside growing expectatio...